- €41.69m
- €81.38m
- €139.11m
Brief: Svas Biosana Q1 Revenue EUR 33.9 Mln
Brief: Svas Biosana FY Net Profit EUR 6.8 Mln
Brief: Svas Biosana FY Prelim Revenue EUR 139.1 Mln
Brief: Svas Biosana CEO Umberto Perillo Resigns, Appoints Chair Filippo Maraniello As CEO
Brief: Svas Biosana 9M Prelim. Revenue EUR 103.4 Mln
Brief: Svas Biosana H1 Net Profit EUR 3.5 Mln
Brief: Svas Biosana Completes Acquisition Of 51% Of Mehos
Brief: Svas Biosana Q1 Revenue EUR 32.7 Mln
Brief: Svas Biosana Unit To Acquire 100% Of Megapharm For EUR 3.0 Mln
Brief: Svas Biosana To Acquire Through Unit Mark Medical 100% Of Hermes Pharma For EUR 3.5 Mln
Brief: Svas Biosana Q3 Prelim. Revenue EUR 85.9 Mln
Brief: Svas Biosana Approves EUR 6 Mln Non-Convertible Bond Issuance
Brief: Svas Biosana H1 Net Profit EUR 2.6 Mln
Brief: Svas Biosana H1 Revenue EUR 58.2 Mln
Brief: Svas Biosana Q1 Total Revenue Up To EUR 28.6 Mln
Brief: Svas Biosana FY EBIT Up To EUR 8.6 Mln
Brief: Svas Biosana FY Prelim Revenue Up To EUR 118.2 Mln
Brief: Svas Biosana 9-Month Total Revenue Up To EUR 81.6 Mln
Brief: Svas Biosana H1 Net Profit Up To EUR 2.3 Mln